ICTHIC

 Friday – April 23rd, 2010 

08.30              Congress Secretariat Opening: Registration

09.00-10.45   Pfizer Satellite Symposium "Cancer-Associated Thrombosis: Can we meet the Challenge?" (Room C)

11.30-13.00   GSK Satellite Symposium "New Developments in LMWH Benefits for Cancer Patients" (Room C)

 Congress Opening       (Auditorium)

14.30-15.00  Opening Remarks: Conference Chairmen

15.00-15.45  Simon Karpatkin Memorial Lecture Platelets: guardians of tumor vasculature - D. Wagner (USA),
Introduced by F.R. Rickles (USA)

15.45-17.40   Plenary Session 1      (Auditorium)
RISK FACTORS FOR THROMBOSIS IN CANCER
Chairs: M. Prins (Netherlands), B. Brenner (Israel)
15.45-16.10 PL-01 Risk stratification and models - A. Khorana (USA)
16.10-16.35 PL-02 The roles of anticoagulants in patients with cancer – A. Lee (Canada)
16.35-17.00    Coffee Break
17.00-17.25 PL-03 Tests predictive of thrombosis in cancer - I. Pabinger (Austria)
Selected Abstract
17.25-17.40 OC-01 Prognostic relevance of asymptomatic venous thromboembolism in patients with cancer - F. Dentali et al. (Italy)

17.45-18.45  Debate     (Auditorium)
THROMBOPROPHYLAXIS DURING CHEMOTHERAPY
Chair: P. Prandoni (Italy)
-Introduction: P. Prandoni
-"NO":  M. Levine (Canada) 
-"YES": G. Agnelli (Italy)

19.00    Welcome Cocktail at the meeting venue (Room "Panoramica)

 Saturday – April 24th, 2010  

 08.30-10.30   Plenary Session 2     (Auditorium)
THROMBOPROPHYLAXIS IN CANCER PATIENTS
Chairs: H.A. Liebman (USA), P. Prandoni (Italy)
08.30-08.55 PL-04 Thromboprophylaxis for medical patients – A.T. Cohen (UK)
08.55-09.20 PL-05 Thromboprophylaxis for cancer surgery – A.K. Kakkar (UK)
09.20-09.45 PL-06 New anticoagulants for patients with cancer – H.R. Buller (The Netherlands)
Selected Abstracts
09.45-10.00 OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study) - A. Maraveyas et al. (UK)
10.00-10.15 OC-03 Randomized phase II trial of an oral factor Xa inhibitor in patients with metastatic cancer on chemotherapy - M.N. Levine et al. (Canada)
10.15-10.30 Discussion

10.30-11.00    Coffee Break  

11.00-13.00  Simultaneous Sessions 1 & 2  

Simultaneous Session 1 (Room C)
BIOLOGY OF BLOOD COAGULATION
Chairs: J. Degen (USA), R. Giavazzi (Italy)
11.00-11.25 SS-01 Signaling and Procoagulant Contributions of Tissue Factor to Cancer Progression – W. Ruf (USA)
11.25-11.50 SS-02 Mechanisms Coupling Thrombin Generation to Colitis-Associated Cancer – J. Palumbo (USA)
11.50-12.15 SS-03 Activation of Clotting Proteins by Tumor Genetic Programs – J.W. Rak (Canada)
Selected Abstracts
12.15-12.30 OC-04 Expression of protease activated receptor-1 and tissue factor in human cancers determined by gene expression profiling and laser capture microdissection - J. van Ryn et al. (Austria, Germany)
12.30-12.45 OC-05 Inhibition of tissue factor by Ixolaris reduces primary tumor growth and metastasis in a murine model of melanoma - A. Da Silva de Oliveira et al. (Brazil, Denmark, USA)
12.45-13.00 Discussion

Simultaneous Session 2 (Auditorium)
BLEEDING ISSUES
Chairs: P. Kamphuisen (The Netherlands), A. Federici (Italy)
11.00-11.25 SS-04 Open issues in Acute Promyelocytic Leukemia - M. Sanz (Spain)
11.25-11.50 SS-05 Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact – F. Elice, F. Rodeghiero (Italy)
11.50-12.15 SS-06 Bleeding complications associated with anticoagulant therapy in patients with cancer – M. Monreal (Spain)
Selected Abstracts
12.15-12.30 OC-06 Frequency, types and management of bleeding episodes in acquired von Willebrand syndrome: a five-year prospective study in a cohort of 18 patients with chronic lympho-myeloproliferative disorders (LPD/MPD) - A.B. Federici et al. (Italy)
12.30-12.45 OC-07 Heparin-antagonist PMX-60056 rapidly and completely reverses heparin anticoagulation in man - R.E. McAllister (USA)
12.45-13.00 Discussion

13.00-14.00  Lunch   /  Sanofi Aventis Lunch Session "VTE in Oncology - From Guidelines to Clinical Practice" (Room C)

14.00-16.00   Plenary Session 3     (Auditorium)
ANTITUMOR PROPERTIES OF ANTICOAGULANTS
Chairs: F.R. Rickles (USA), G. Palareti (Italy)
14.00-14.10 PL-07 Update on the predictive value of D-dimer in patients with idiopathic VTE – G. Palareti (Italy)
14.10-14.35 PL-08 Experimental approaches and new drugs - L. Borsig (Switzerland)
14.35-15.00 PL-09 Heparanase procoagulant effects and inhibition by heparins – Y. Nadir (Israel)
15.00-15.25 PL-10 Anticoagulants in mouse models – C. J. Van Noorden (Netherlands)
15.25-15.50 PL-11 Clinical evidence for use of LMWH as adjuvant therapy in patients with cancer –   H.R. Büller (Netherlands)
Selected Abstract
15.50-16.05  OC-08 Adjuvant Bemiparin in small cell lung cancer: results from the ABEL Study - R. Lecumberri et al., on behalf of the ABEL Investigators (Spain)

16.10-16.30    Coffee Break  

16.30-18.30  Simultaneous Sessions 3 & 4  

Simultaneous Session 3 (Room C)
MICROPARTICLES IN TUMOR GROWTH
Chairs:  F. Dignat-George (France), F.R. Rickles (USA)
16.30-16.55 SS-07 Membrane microparticles in VTE and cancer: Actors or Artifacts – N. Key (USA)
16.55-17.20 SS-08 Microparticles in cancer disease and progression - J-M. Freyssinet (France)
17.20-17.45 SS-09 Predictive value of TF-bearing microparticles in VTE/cancer patients – J.I. Zwicker (USA)
Selected Abstracts
17.45-18.00 OC-09 Tissue factor-bearing microparticles released from tumor cells: Relationship of particle size to procoagulant activity - J.L. Francis et al. (USA)
18.00-18.15 OC-10 Involvement of cancer cell-derived microparticles on thrombus formation in vivo - C. Dubois et al. (France)
18.15-18.30 OC The role of breast cancer cells microparticles in thrombogenicity following chemotherapy - A. Aharon et al. (Israel)

Simultaneous Session 4 (Auditorium)
THROMBOTIC COMPLICATIONS
Chairs: T. Barbui (Italy), M.-M. Samama (France)
16.30-16.55 SS-10 Population based studies – M.B. Donati (Italy)
16.55-17.20 SS-11 VTE in acute leukemia, lymphoma and myeloma – T. Wun (USA)
17.20-17.45 SS-12 The risk of cancer in OAT patients - B. Cosmi (Italy)
17.45-18.10 SS-13 Paroxysmal nocturnal hemoglobinuria and thrombosis - I. Weitz (USA)
Selected Abstract
18.10 -18.25 OC-11 Residual vein thrombosis (RVT) for assessing the optimal management of deep vein thrombosis in cancer patients: an interim analysis of the cancer DACUS study - A. Malato et al. (Italy)

20.00  Gala Dinner at the Hotel Regina Palace 

 Sunday – April 25th, 2010  

08.30-10.30   Plenary Session 4      (Auditorium)
UPDATED GUIDELINES FOR PREVENTION AND TREATMENT OF VTE IN CANCER
Chairs: G. Johnson (USA), A. Falanga (Italy)
08.30-08.55 PL-12 French guidelines – D. Farge-Bancel (France)
08.55-09.20 PL-13 ESMO guidelines – R. Labianca (Italy)
09.20-09.45 PL-14 ASCO guidelines – G. Lyman (USA)
09.45-10.10 PL-15 NCCN  guidelines – M. Streiff (USA)
10.10-10.30 Round Table on Unresolved Issues - Chair: F.R. Rickles

10.30-11.00 Coffee Break  

11.00-13.00  Simultaneous Sessions 5 & 6  

Simultaneous Session 5 (Room C)
TARGETING HEMOSTATIC SYSTEM AS THERAPY FOR CANCER
Chairs: H. ten Cate (Netherlands), P.M. Sandset (Norway)
11.00-11.25 SS-14 Targeting tumor vessel anionic phospholipids: experimental and clinical studies -  P.E. Thorpe (USA)
11.25-11.50 SS-15 The role of activated protein C in tumor metastasis – G.L. Van Sluis (Netherlands)
11.50-12.15 SS-16 Vascular targeting with TF constructs – W.E. Berdel (Germany)
Selected Abstracts
12.15-12.30 OC-12 Tissue factor phosphorylation requires protease activated receptor-2 expression: Correlation with the prognosis of human breast cancer - M. Belting et al. (Sweden, USA)
12.30-12.45 OC-13 Enhanced expression of MDA-9/syntenin induced through the tissue-factor pathway in melanoma promotes tumor cell migration and invasion - H. Boukerche et al. (France, USA)
12.45-13.00 Discussion

Simultaneous Session 6 (Auditorium)
GENDER- AND AGE-RELATED ISSUES
Chairs: U. Nowak-Göttl (Germany), B. Brenner (Israel)
11.00-11.25 SS-17 Thrombohemorrhagic complications in children with hemato-oncological diseases – M.C. Putti (Italy)
11.25-11.50 SS-18 Epidemiology and risk factors for VTE in female cancer - N. Kuderer (USA)
11.50-12.15 SS-19 Thrombosis in male cancer – J. Beyer-Westendorf (Germany)
Selected Abstracts
12.15-12.30 OC-14 Reversible posterior leukoencephalopathy syndrome: the role of von Willebrand Factor and ADAMTS13 in children with ALL during induction therapy - J.D.A. Carneiro et al. (Brazil)
12.30-12.45 OC-15 Hemostatic activation, fibrinolysis and angiogenesis are increased in patients with advanced prostate cancer (PC) and decrease in response to hormonal therapy - J.E. Arnason et al. (USA)
12.45-13.00 Discussion

13.00-14.00  Lunch

14.00-15.15    Poster Discussion Sessions 1-2-3   

-Poster Discussion Session 1             Room C

EPIDEMIOLOGY  - Chairs: M. Mandalà (Italy), M. Verso (Italy)

-Poster Discussion Session 2             Room D

HEMOSTATIC ACTIVATION AND CANCER PROGRESSION - Chairs: H.H.Versteeg (The Netherlands), R. Lorenzet (Italy)

-Poster Discussion Session 3             Room E

HYPERCOAGULATION AND THROMBO/HEMORRHAGIC RISK BIOMARKERS - Chairs: A. D'Angelo (Italy), D. Prisco (Italy)

15.45-17.00    Poster Discussion Sessions 4-5-6 

-Poster Discussion Session 4             Room D

MICROPARTICLES - Chairs: E. Castoldi (The Netherlands), M. Cattaneo (Italy)

-Poster Discussion Session 5             Room C

PROPHYLAXIS AND TREATMENT - Chairs: G. Johnson (USA), S. Siragusa (Italy)

-Poster Discussion Session 6             Room E

TARGETING THE HEMOSTATIC SYSTEM - Chairs: M. Camera (Italy), M.L. Randi (Italy)

17.00    Meeting Closed  

19.30   Farewell Party on the island "Isola Bella"